OncoMatch/Clinical Trials/NCT07258511
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Is NCT07258511 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including JNJ-79635322 and Teclistamab for multiple myeloma.
Treatment: JNJ-79635322 · Teclistamab — The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
Must have received: immunomodulatory drug
Must have received: anti-cd38 antibody
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- USC Norris Comprehensive Cancer Center · Los Angeles, California
- University of Connecticut Health Center · Farmington, Connecticut
- Yale Cancer Center · New Haven, Connecticut
- Florida Cancer Specialists & Research Institute · Fort Myers, Florida
- Emory University · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify